Noticias y Actividades de PMV Pharmaceuticals

PMV Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización PMVP (US).

Ver el organigrama con sus 22 ejecutivos principales

Biografías más buscadas en PMV Pharmaceuticals

• David Mack, Director, President and Chief Executive Officer
• Laurie Stelzer, Chairman of the Board (starts on Jun 4 2026)
• Arnold Levine, Director

Recientes movimientos de ejecutivos en PMV Pharmaceuticals

• Laurie Stelzer se incorporará a la empresa como Chairman of the Board el 4 de jun.. de 2026  (noticia publicada el 22 de abril de 2026).
• Richard Heyman, Chairman of the Board, abandonará la empresa el 4 de jun.. de 2026  (noticia publicada el 22 de abril de 2026).
• Laura De Leon que ha sido Vice President and Head of Clinical Operations, ha ascendido a Vice President, Clinical Development Operations  (noticia publicada el 22 de abril de 2026).

Crear su alerta
para seguir los movimientos de los ejecutivos en PMV Pharmaceuticals.

PMV Pharmaceuticals tiene 1.913 competidores entre los que se incluyen Sanofi (Francia), Eli Lilly (Estados Unidos) y Moderna (Estados Unidos).

Popular M&A news in Farmacia

• Contraline acaba de anunciar una recaudación de fondos de 93 millones de dólares. (publicado el 3 de junio de 2026).
• Hims & Hers ha Eucalyptus adquirido (publicado el 2 de junio de 2026).
• Apotex ha presentado su expediente de OPI. Su símbolo de cotización será TSX. (publicado el 2 de junio de 2026).

Otros contactos sugeridos en el sector Farmacia

• Joaquin Duato - Chief Executive Officer and Chairman of the Board en Johnson & Johnson
• Richard Saynor - Chief Executive Officer en Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board en Abbott

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de PMV Pharmaceuticals

• PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors | PMV Pharmaceuticals, Inc.
• PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference | PMV Pharmaceuticals, Inc.
• PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation | PMV Pharmaceuticals, Inc.
• PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | PMV Pharmaceuticals, Inc.
• PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights | PMV Pharmaceuticals, Inc.
• PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | PMV Pharmaceuticals, Inc.
• PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights | PMV Pharmaceuticals, Inc.
• PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference | PMV Pharmaceuticals, Inc.
• PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day | PMV Pharmaceuticals, Inc.
• PMV Pharma Announces Changes to its Board of Directors | PMV Pharmaceuticals, Inc.
• View more press releases Close

Redes sociales sobre PMV Pharmaceuticals

• PMV Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• PMV Pharmaceuticals en LinkedIn, Twitter y YouTube